Our Story
Helping reduce pain and suffering by using chemistry against cancer
JSK Therapeutics™ (JSKT) was founded in order to develop new anti-cancer therapeutics with fewer side effects.
The lead compound we will bring to market is JS-K, a first-in-class nitric oxide (NO)-generating compound of the arylated diazeniumdiolate class.
JS-K was developed through collaboration between the team of Dr. Larry Keefer at the National Cancer Institute (NCI) and Dr. Paul Shami’s laboratory at the University of Utah.